Yang

1	The First Insight into the Hereditary Fusion Gene Landscape of
2	Amyotrophic Lateral Sclerosis
3	
4	Jinfeng Yang ¹ , Fenghua Yuan ² , Anna Palovcak ² , Ling Fei ³ , Noah Zhuo ⁴ , NYGC ALS
5	Consortium*, Yanbin Zhang ² , Degen Zhuo ⁴
6	
7 8 9 10 11 12 13 14	¹ Department of Anesthesiology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China; ² the Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, Florida 33136, ³ Dept of Cardiology, The Affiliated Hospital of North Sichuan, Chengdu Xinhua Hospital, Cheng Du, 610055, China; ⁴ SplicinagCodes, BioTailor Inc, 7328 SW 82 nd Street, #B114, Miami, FL 33143 USA
15 16	Miami, FL 33143 USA, <u>degen.zhuo@gmail.com</u>
17	Abstract
10	

18 Amyotrophic lateral sclerosis (ALS) is a progressive nervous system disease that causes loss of 19 muscle control. Over 30 mutated genes are associated with ASL. However, 90-95% of ASL cases 20 have been found without a family history. Here, we have analyzed RNA-Seq data of NYGC ALS 21 Consortium and identified fusion transcripts from ASL patients and non-neurologic controls (NNC). In 22 this study, we combined previously-curated 1180 monozygotic (MZ) hereditary fusion genes (HFGs), 23 and 204 HFGs discovered from NNC to analyze ASL fusion transcripts and identified 348 HFGs. 24 Comparative analysis between ASL and GTEx shows that 139 HFGs are associated with ASL and 25 ranged from 10.4% to 98.7% of 77 ASL patients. The most recurrent HFG is ZNF528-ZNF880, 26 detected in 98.7% of 77 ASL patients and 4.5% of 133 GTEx brain cortexes. Alignments of HFG 27 transcripts from ASL with fusion transcripts from mesial temporal lobe epilepsy (MTLE) and Alzheimer's 28 disease (AD) showed that 43.9% and 11.6% of the ASL HFGs were present in MTLE and AD, 29 respectively. The most recurrent and common HFG among ASL, MTLE, and AD was ADAMTSL3-30 SH3GL3, which behaves like ubiquitously-expressed SH3GL3-ADAMTSL3 epigenetic fusion gene 31 (EFG) and shows that ADAMTSL3-SH3GL3 is a potential dormant or differentially-expressed HFG 32 (dHFG), suggesting that they have common pathophysiological mechanisms. These HFGs associated 33 with ASL have shown that HFGs are the missing genetic heritability and provide novel therapeutic 34 targets for more efficient therapeutic drugs and methods to treat and cure many neurological diseases. 35

Yang

1	
2	
3	Keywords: Hereditary fusion gene, Amyotrophic Lateral Sclerosis, epilepsy, Alzheimer's disease, RNA-
4	Seq, Epigenetic fusion gene
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	Introduction
20	Amyotrophic lateral sclerosis (ALS) is a progressive, fatal neurodegenerative disease characterized by
21	progressive degenerative changes in upper and lower motor neurons that overlap with frontotemporal
22	lobar degeneration clinically, morphologically and genetically ¹ . ASL clinical symptoms include
23	weakness of the bulbar and limb muscles, hyperreflexia, spasticity of the arms and legs, and respiratory
24	failure ^{2, 3} . These symptoms start with onset typically in the fifth or sixth decade of life, and death
	The First Insight into the Hereditary Fusion Gene Landscape of ASL

Yang

1 commonly occurs within 2-4 years of diagnosis². ALS is closely related to frontotemporal dementia 2 (FTD), a progressive neurodegenerative disease characterized by degeneration of the frontal and 3 temporal lobes of the brain, resulting in behavior, personality, and language disturbances. Up to 15% 4 of ALS patients are also diagnosed with frontotemporal dementia (FTD-ALS patients)⁴. Many studies 5 have shown clinical, pathological, and genetic commonalities between them. Therefore, ASL and FTD 6 have now considered two manifestations of one disease continuum of the FTD-ALS spectrums⁵.

7

8 ALS is associated with over 30 mutated genes, including SOD1, TARDBP, FUS, OPTN, VCP, 9 UBQLN2, C9ORF72, and PFN1⁶⁻⁸. However, they are typically present in fewer than 5-10% of all ALS patients, and most ASL cases remain unexplained^{9 10}. Genome-wide associations (GWAS) have 10 11 genotyped numerous single nucleotide polymorphisms (SNPs) present in at least 1% of the human 12 population¹¹ and identified some common and rare SNPs associated with ASL across the genome ¹²⁻¹⁴. 13 More recently, the discovery of genes associated with ASL has been shifted to next-generation 14 sequencing, such as whole-genome sequencing (WGS) and RNA-Seq. Many WGS studies have confirmed previous findings and identified many common and rare variants associated with ASL ^{15, 16}. 15 16 Brown et al. have performed RNA-Seg analysis on the ASL postmortem cortex samples of NYGC ALS 17 Consortium and found that TDP-43 loss resulted from retrotransposon and ALS-risk SNPs drive missplicing and depletion of UNC13A^{17, 18}. Many studies have speculated that structural variants may be a 18 source of missing ASL heritability ^{10, 19}. More recently, Raghav et al. analyzed RNA-Seq data from 19 20 Target ALS and the NYGC ALS Consortium and identified 607 unique fusion genes, some significantly higher in ASL samples than those in control ²⁰, suggesting that fusion genes generated by structural 21 22 variants may be responsible for ASL.

23

Yang

1 As discussed above, advances in RNA-Seq have made it possible to discover fusion transcripts 2 generated by structural variants. However, misconceptions and poor algorithms for repetitive sequences have made fusion transcripts discovered incomplete, irreproducible, and unreliable ²¹. In 3 4 order to overcome these problems, we have used the splicingcode theory to develop SCIF 5 (SplicingCodes Identify Fusion Genes) to discover more reproducible and accurate fusion transcripts and make it possible to compare and analyze data among different experiments²². Validation of highly-6 7 recurrent fusion genes has cast doubts that fusion genes are cancerous and generated from somatic 8 KANSARL (KANSL1-ARL17A) is validated as the first predisposition genomic abnormalities. 9 (hereditary) fusion genes specific to 29% of populations of European ancestry ²². TPM4-KLF2. 10 detected in 92.2% of 727 multiple myeloma patients and initially thought to be a multiple myelomaspecific somatic fusion gene, has been detected in all five healthy bone marrows²³. Based on their 11 12 genomic structures, genetics, and evolution, we have classified the fusion genes into somatic, 13 epigenetic, and hereditary²⁴. Hereditary fusion genes (HFGs) are the fusion genes that offspring inherit from their parents, excluding readthrough transcripts of two identical-stand neighboring genes²⁵, named 14 epigenetic fusion genes (EFGs)²⁴. 15 Furthermore, we have used 1180 HFGs identified from 16 monozygotic (MZ) twins to analyze fusion transcripts from multiple myeloma and acute myeloid 17 leukemia (AML) and discovered that HFGs are dominant inherited factors and mutated genes have played minor roles in cancer inheritance ^{26, 27}. EFGs have reflected developmentally interactive 18 19 consequences between genetic and environmental factors^{23, 27}.

20

In this study, we analyzed RNA-Seq data of NYGC ALS Consortium and identified large numbers of fusion transcripts from RNA-Seq data of ASL patients. Surprisingly, we have observed large numbers of highly-recurrent fusion genes from their non-neurological controls, 204 of which are determined to be HFGs. We have used these newly-identified HFGs and the previously-curated 1180 HFGs to analyze The First Insight into the Hereditary Fusion Gene Landscape of ASL

Yang

1 the fusion transcripts. From 358 HFGs, we have identified 139 HFGs associated with ASL ranging from 2 10.4% to 98.7% of ASL patients. We have discovered that many highly recurrent ASL HFGs have also 3 been detected in mesial temporal lobe epilepsy (MTLE) and Alzheimer's disease (AD), suggesting 4 common pathophysiological mechanisms²⁸. ADAMTSL3-SH3GL3 HFG behaves like SH3GL3-5 ADAMTSL3 EFG, suggesting it has a much higher recurrent frequency than its GTEx brain cortex 6 counterpart. This study has shown that HFGs are the missing heritability of complex diseases and 7 traits and provides potential therapeutic targets for more efficient novel therapeutic drugs and methods 8 for ASL and other neurological diseases.

9

10 Materials and Methods

11 Materials

12 Amyotrophic lateral sclerosis RNA-Seq data: Amyotrophic lateral sclerosis (ALS) RNA-Seq data 13 (GEO: GSE124439) was downloaded from NCBI 14 (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA512012). The ASL dataset contained 176 RNA-Seq 15 data and included 145 samples of ASL spectrum from 77 unique ASL patients, 14 samples of other 16 neurological disorders (named as OND to avoid confusion) from seven unique individuals, and 17 non-17 neurological controls (NNC) from 12 unique individuals. The RNA-Seg was performed on postmortem 18 patients' frontal cortex, medial motor cortex, and lateral motor cortex.

19 Mesial temporal lobe epilepsy RNA-Seq data: The mesial temporal lobe epilepsy (MTLE) RNA-Seq 20 (GEO: data GSE134697) downloaded from NCBI was 21 (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA556159). The MTLE RNA-Seg dataset contained the 22 hippocampus and neocortex of 17 MTLE patients and two healthy controls. This study used only RNA-23 Seq data from the neocortex of 17 MTLE patients.

24

Yang

Alzheimer's disease RNA-Seq data: The Alzheimer's disease (AD) RNA-Seq data (GEO: GSE53697)
 was downloaded from NCBI (<u>https://www.ncbi.nlm.nih.gov/bioproject/PRJNA232669</u>). The AD data
 had 17 brain samples, including nine patients and eight controls.

4

GTEx brain cortex RNA-Seq data: the Genotype-Tissue Expression (GTEx) RNA-Seq data (dbGaP:
phs000424) was downloaded from NCBI (<u>https://www.ncbi.nlm.nih.gov/bioproject/PRJNA75899</u>). We
selected and performed RNA-Seq data from 133 brain cortexes of 133 unique individuals as the healthy
controls.

9

10 Methods

11 Identification of fusion transcripts from RNA-Seq data: We used SCIF (SplicingCodes Identify 12 Fusion Genes) to perform RNA-Seg analysis at the default conditions²². Since SCIF used raw RNA-13 Seq reads without any assembly to discover the fusion junctions and followed by extended sequence 14 alignments, each RNA-Seq read was either a fusion transcript or not a fusion transcript. Human was 15 not involved in determining whether a sample with a fusion junction or a sample with three fusion 16 junctions was hereditary fusion gene-positive. However, one of the worst defects in discovering the 17 hereditary fusion genes from RNA-Seq data was that levels of gene expression, RNA-Seq qualities, 18 and the number of RNA-Seq reads would affect the analysis. Consequently, we must take caution to 19 handle and analyzing data.

Statistical analysis: To compare two different populations, we have used the two-tailed Z score analyses to determine whether the two populations differ significantly in their genetic characteristics. We set the null hypothesis to be that there is no difference between the two population proportions. Z scores are calculated based on the following formula:

$$Z = \frac{(\overline{p}_1 - \overline{p}_2) - 0}{\sqrt{\overline{p}(1 - \overline{p})\left(\frac{1}{n_1} + \frac{1}{n_2}\right)}}$$

24

Yang

- 1 \bar{p}_1 and \bar{p}_2 were the population standard errors of p_1 and p_2 .
- 2 $\bar{p}_{1} = x_1 / n_1; \bar{p}_2 = x_2 / n_2; \bar{p} = (x_1 + x_2) / (n_1 + n_2).$

3 To perform HFG comparisons between ASL and GTEx, if the recurrent frequency was zero in GTEx,

- 4 we used one to replace zero of the raw count to avoid the infinite.
- 5
- 6
- 7 Results

8 Discovering novel HFGs from RNA-Seq data of the non-neurologic controls.

9 We downloaded the RNA-Seg data of NYGC ALS Consortium (GEO: GSE124439), which contained a 10 total of 176 frontal cortex/motor cortex, including 145 samples of ASL spectrum from 77 unique ASL 11 patients, 14 samples of other neurological disorders (named as OND to avoid confusions) from seven 12 unique individuals, and 17 non-neurological controls (NNC) from 12 unique individuals (Fig.1a). We 13 used SCIF to analyze RNA-Seq data of this dataset and identified 64,000 fusion transcripts from 14 samples of ASL and OND and 8,190 fusion transcripts from 12 non-neurological controls. Manual 15 inspections showed that fusion genes had been discovered at such high recurrent frequencies in non-16 neurological samples that traditional logic and biological models cannot explain. For example. 17 ADAMTSL3-SH3GL3, an inversion of SH3GL3-ADAMTSL3, had been observed in all 12 non-18 neurological controls. If structural variants generating a fusion gene per individual had a rate of 3.6x10⁻ ² ^{29, 30}, the chance of all 12 NNC individuals having the identical ADAMTSL3-SH3GL3 fusion gene 19 generated by random somatic genomic alterations was 4.7X10⁻¹⁸ and a mathematically impossible 20 event, suggesting it had to be inherited from their parents²⁴. Fig.1b shows the procedure to discover 21 22 hereditary fusion genes (HFGs) from NNC. If we set the cutoff of recurrent frequencies at two or more 23 in 12 NNC individuals, the minimum recurrent frequencies of 16.7% were at least 11.9 fold of 1.4% of 24 the random chance. We initially identified 257 putative HFG transcripts whose recurrent frequencies The First Insight into the Hereditary Fusion Gene Landscape of ASL

Yang

ranged from 16.7% to 100%. After performing Blast analyses in Aceview and NCBI, we removed 24 EFG transcripts and potential alternative-spliced transcripts and obtained 233 HFG transcripts encoded by 204 HFGs (STable 1). Out of 233 HFG transcripts, we discovered that 33 (16.2%) HFGs coding for 38 transcripts were from tandem gene duplications (Stable 2), suggesting that tandem gene duplications were essential for genotype and phenotype diversities²⁴.

6

7 Identifications of HFGs from RNA-Seq data of amyotrophic lateral sclerosis (ALS) patients

8 Next, we used these 204 HFGs discovered from NNC plus the previously curated 1180 MZ HFGs²⁴ 9 (Fig.1c) to analyze the total fusion transcripts of 154 ASL and 14 OND samples. We identified 358 10 HFGs encoding 870 HFG transcripts, ranging from 0.6% to 98.1% of 159 ASL and OND samples, the 11 average of which was 2.4 per HFG, suggesting that many HFGs had multiple isoforms. Fig.1d showed 12 that 42 out of 358 HFGs were present in both NNC and MZ HFG datasets and counted for 21.4% of 13 NNC 196 HFGs, supporting our rationales of discovering novel HFGs from NNC. Further analysis 14 showed that only an additional 17 of 196 HFGs were present in GTEx blood samples (data not shown) 15 and suggested that most 196 HFGs were potentially differentially expressed and not expressed in blood 16 and other samples. This differential HFG expression potentially masked the accuracy of the HFG 17 frequencies detected in blood samples. Since these HFG transcripts were from the frontal cortex, 18 medial motor cortex, and lateral motor cortex of ASL and OND samples, we must study whether these 19 HFGs were differentially expressed among the frontal cortex and medial and lateral motor cortexes and 20 affected the results.

21

To understand whether HFGs were differentially expressed and affected HFG results analyzed afterward, we performed comparative analyses of HFGs among the frontal cortexes, medial motor cortex, and lateral motor cortex. After inspecting the HFG distributions of the frontal cortexes, medial The First Insight into the Hereditary Fusion Gene Landscape of ASL

Yang

1 motor cortex, and lateral motor cortexes, we found no HFGs with high recurrent frequencies were 2 differentially expressed among these three brain tissues. STable 3 showed that 179 HFGs were 3 encoding 268 HFG transcripts in all frontal cortex, medial motor cortex, and lateral cortex. Majorities of 4 differences in the HFG transcripts among the three groups were small and statistically insignificant. We 5 identified 22 ASL patients with data from all frontal cortex, medial motor cortex, and lateral motor 6 cortex, similar to 22 three-duplication experiments. We performed a comparative data analysis of these 7 22 ASL patients. STable 4 showed that we identified 29 HFGs encoding 38 HFG transcripts 8 expressed in all frontal cortex, medial motor cortex, and lateral motor cortex and suggested that these 9 HFGs discovered by SCIF were highly reproducible. For example, ZNF528-ZNF880 and SNORD114 -10 MEG8_ a were observed in all three tissues of 21 of 22 ASL patients and showed 100% reproducibility. Here, SNORD114_ was an abbreviated SNORD114-1-SNORD114-2-SNORD114-3²⁵ while MEG8 11 12 was MEG8-SNORD112-SNORD113-3²⁵. Careful inspections showed that some HFGs were 13 alternatively spliced. For example, the frequency difference of the main SNORD114 -MEG8 isoform 14 a was within statistical errors among the frontal cortex, medial motor cortex, and lateral cortex. 15 However, the recurrent frequencies of the SNORD114 -MEG8 isoform c in the medial motor cortex 16 and lateral motor cortexes were 16.4% and 13.7% higher than their counterpart in the frontal cortex. 17 They reflected alternatively splicing in the frontal, medial, and lateral motor cortexes. Since we 18 generally used the recurrent frequency of the main HFG isoform as the HFG recurrent frequency for 19 genotype analysis, we could combine HFG data from the frontal cortex and medial and lateral motor 20 cortexes to perform further analysis.

21

22 Identification and characterization of HFGs associated with ASL

We used the combined HFG dataset described above to analyze the total fusion transcripts from 77
 ASL patients. We identified 346 HFGs encoding 819 HFG transcripts whose recurrent frequencies
 The First Insight into the Hereditary Fusion Gene Landscape of ASL

Yang

1 ranged from 1.3% to 98.7%. 345 (42.1%) HFG transcripts were detected in only one ASL patient, 2 suggesting they were either causal HFGs or lowly-expressed HFG transcripts. For a more convenient 3 analysis, we set the cutoff of the recurrent frequency at 10%. STable 5 showed that we observed 147 4 HFGs coding for 190 HFG transcripts ranging from 10.4% to 98.7%. Table 1 showed that the top 5 sixteen HFGs encoding twenty-one HFG transcripts with recurrent frequencies of ≥50% ranged from 6 51.3% to 98.7%. Fig.2a showed that the most recurrent ZNF528-ZNF880, an inversion of ZNF880-7 ZNF528 on the plus strand of chromosome 19q13.41, was detected in 76 (98.7%) of 77 ASL patients 8 and encoded a truncated zinc finger protein 880 without 35 aa N-terminus sequences (S Fig.1). Fig.2b 9 showed that SNORD114 -MEG8 was one of the most highly-expressed HFGs and coded for 20 10 isoforms, three of which were 92.1%, 85.5%, and 53.9% (Table 1). When we performed a comparative 11 analysis between ASL and NCC, many HFG differences were insignificant. For example, ERMP-12 KIAA2026, reported in stomach cancer³¹, was detected in 75% of 75 ASL patients and 12 NNC 13 samples. As described previously, if structural variants generating a fusion gene per individual had a rate of 3.6x10^{-2 29, 30}, the chance of having nine NNC individuals who possessed ERMP-KIAA2026³¹ 14 by random somatic genomic abnormalities was 1.0X10⁻¹³ and a mathematically-impossible event. It 15 16 was most likely that NNC was extraordinarily distorted for some unexplained reasons and unsuitable to 17 use as a standard control.

To overcome the NNC distortion, we selected RNA-Seq data from 133 GTEx brain cortexes as healthy controls. We used 346 HFG from 77 ASL patients to analyze 26,000 fusion transcripts discovered from the GTEx brain cortexes and identified 165 HFGs coding for 188 HFG transcripts from GTEx brain cortexes, suggesting that 47.7% of 346 ASL HFGs were present in the GTEx brain cortexes. The most recurrent GTEx HFGs were *KANSARL* (*KANSL1-ARL17A*)²² and *TRNAN35-FAM91A3P* (Fig.2c) HFGs were detected in 34.6% and 31.6% of 133 GTEx brain cortexes. In comparison, 56.6% of the ASL

Yang

HFGs with recurrent frequencies of ≥10% overlapped with HFGs of GTEx brain cortexes, suggesting
 that the more recurrent ASL HFGs were, the more likely they were present in GTEx brain cortexes.

3 Next, we performed a comparative analysis of the HFG differences between ASL and GTEx. We 4 discovered that 139 out of 147 ASL HFGs ranged from 10.4% to 98.7% and were 1.2-244 folds higher 5 than their GTEx brain cortex counterparts, which were statistically significant (STable 5). Table 1 6 showed that sixteen HFGs were encoding twenty-one HFG transcripts, whose recurrent frequencies 7 ranged from 51.3% to 98.7% and were 1.8 to 120 folds of the GTEx brain cortex counterparts, which 8 were statistically significant by the Z-test. Table 1 showed that ZNF528-ZNF880 (Fig.2a) was the most 9 recurrent HFG detected in 98.7% of 77 ASL patients. In comparison, it was detected in 4.5% of 133 10 GTEx brain cortexes. The former was 21 folds of the latter, suggesting that ZNF528-ZNF880 HFG was 11 necessary for ASL initiation and prognosis. The most significant difference of HFG recurrent 12 frequencies between ASL and GTEx was SNORD114 -MEG8 (Fig.2b), a local inversion of SNORD114-1-SNORD114-2-SNORD114-3 EFG²⁵ and MEG8-SNORD112-SNORD113-3 EFG²⁵, 13 14 resulted in potentially more diverse expression of snoRNAs. TRNAN35-FAM91A3P was the HFG with 15 the least frequency difference between ASL and GTEx. It was an inversion of TRNAN35, encoding 16 transfer RNA asparagine 35 and FAM91A3P, coding for the family with sequence similarity 91 member 17 A3 pseudogene (Fig.2c), detected in 31.6% of GTEx brain cortexes.

Table 1 showed that *TRNAN35-FAM91A3P*, *TRNAN35-SRGAP2P2*, and *TRNAN35-SEC22B* were
three *TRNAN35*-fused HFGs coded for putative 124 a.a, 177 a.a, 171 a.a, and 67 a.a polypeptides,
which were potentially regulated by *TRNAN35* via asparaginyl-tRNA synthetase and formed a natural
network²⁴. Four HFGs, including *SDHAP2-SDHAP2*, *YY1AP1-YY1AP1* (S Fig.2), *FMNL2-FMNL2*(SFig.3), and *SPECC1L-SPECC1L*, were shown to be generated via gene tandem duplications,
suggesting that tandem gene duplications were more widespread than what was reported previously³². *FMNL2-FMNL2* encoded an FMNL2 protein with two exon insertions. *FMNL2* has been shown to

Yang

regulate gliovascular interactions and is associated with vascular risk factors and cerebrovascular pathology in Alzheimer's disease³³. *YY1AP1-YY1AP1* encoded a truncated YY1-associated protein 1. A genome-wide sequence showed that a frameshift mutation and a large deletion in *YY1AP1* resulted in a girl with a panvascular artery disease³⁴. *SPECC1L-SPECC1L* seemed to encode intact SPECC1L protein. It had been shown that mutated *SPECC1L* caused congenital diaphragmatic hernia -- a prominent feature of a *SPECC1L*-related syndrome³⁵.

7

8 Identification of common HFGs among ASL, Alzheimer's disease (AD), and mesial temporal lobe 9 epilepsy (MTLE)

10 To investigate whether the OND had different HFGs, fusion transcripts identified from 14 OND samples 11 of seven patients were aligned with ASL HFG transcripts. We identified 206 HFGs encoding 318 HFG 12 transcripts whose recurrent frequencies ranged from 14.3% to 100%, suggesting that 59.5% of 346 13 ASL HFGs were also found in seven OND patients, many of which had much higher recurrent 14 frequencies in OND than in ASL. SNORD114_-MEG8_, FMNL2-FMNL2, and ADAMTSL3-SH3GL3 15 were the three top HFGs detected in all seven (100%) OND, while they were observed in 90.1%, 16 68.8%, and 87% of 77 ASL patients. Many other HFGs associated with ASL were also observed in 17 OND at similar or even higher recurrent frequencies than their ASL counterparts. 59.5% of ASL HFGs 18 observed in OND raised interesting questions about whether other neurological diseases, such as 19 temporal lobe epilepsy (MTLE) and Alzheimer's disease (AD), had common HFGs.

We used 819 HFG transcripts to analyze fusion transcripts of nine advanced AD patients ³⁶ and 17 neocortex samples of seventeen MTLE patients produced for a 2019 failed NIH grant application. We discovered that 152 HFGs coding for 214 HFG transcripts overlapped between ASL and MTLE and counted for 43.9% of 346 HFGs discovered in ASL, suggesting that ASL and MTLE had significantly inherited genetic similarity. In comparison, when 817 HFG fusion transcripts were aligned with fusion The First Insight into the Hereditary Fusion Gene Landscape of ASL

Yang

transcripts from nine AD patients, we identified only 40 HFGs encoding 74 HFG transcripts, accounting
 for only 11.6% of 346 HFGs observed in ASL and suggested that AD was much more divergent from
 ASL than MTLE.

Table 2 showed comparisons of highly-recurrent sixteen HFGs between ASL, MTLE, and AD, while the
GTEx brain cortex counterparts were used as controls. All 21 HFG transcripts of sixteen ASL HFGs
were present in seventeen MTLE patients. Surprisingly, The *TRNAN35-FAM91A3P*, *TRNAN35- SRGAP2P2*, and *TRNAN35-SEC22B* recurrent frequencies in ASL were 2.3 to 3.8 folds of the MTLE
counterparts. The *TRNAN35-FAM91A3P* recurrent frequency of MTLE patients was 23.5% and lower
than 31.6% of GTEx brain cortexes (Table 2).

Table 2 also showed that only half of the top sixteen highly recurrent ASL HFGs were detected in AD patients, while another half was absent in AD patients. The most notable HFGs absent in AD patients were *YY1AP1-YY1AP1*, *FMNL2-FMNL2*, and *SPECC1L-SPECC1L* generated by tandem duplications. The most critical HFGs shared between ASL and AD were *ZNF528-ZNF880* and *ADAMTSL3-SH3GL3*, detected in 98.7% and 87% of 77 ASL patients, and 88.9%, and 100% of nine AD patients, respectively. These highly recurrent HFGs were present in ASL, MTLE, and AD and supported that many neurological diseases might have common pathophysiological mechanisms²⁸.

17

18 Identification of ADAMTSL3-SH3GL3 as a potentially dormant or differentially-expressed HFG

ADAMTSL3-SH3GL3, reported recently ^{20, 37}, was an inversion of SH3GL3-ADAMTSL3³⁸ on 15q25, encoding thirteen isoforms and coded for 42 alternatively-spliced isoforms (Fig.3). Its ADAMTSL3-SH3GL3 main isoform a was expressed only at 19% of the KANSARL (KANASL1-ARL17A) main isoform level and encoded a conceptual 202 aa ADAMTSL3-SH3GL3 fusion protein over two-thirds of which was from SH3GL3. Since SH3GL3 was most expressed only in the brain and testis while ADAMTSL3 was expressed at a minimum level in the brain but at high levels in other tissues, The First Insight into the Hereditary Fusion Gene Landscape of ASL

Yang

1 ADAMTSL3-SH3GL3 may alter SH3GL3 expression patterns and regulations. Table 3 showed that 2 ADAMTSL3-SH3GL3 was also detected in ASL, OND, AD, and MTLE and ranged from 82.4% to 100%. 3 Surprisingly, ADAMTSL3-SH3GL3 was also detected in 100% of 12 NNC samples and 87.5% of eight 4 AD-healthy controls, significantly higher than 1.5% of 133 GTEx brain cortexes (Table 3). To address 5 these enormous gaps among these controls, we used SH3GL3-ADAMTSL3, recently reported³⁸, as an 6 example to compare both HFG expression patterns and behaviors. Table 3 showed that SH3GL3-7 ADAMTSL3, coding for an intact ADAMTS-like 3 protein, was ubiquitously expressed in all datasets 8 analyzed except for GTEx brain cortexes, in 7.5% of which it was detected. Since the SH3GL3-9 ADAMTSL3 locus was present in almost all human individuals, its expression might have been induced 10 due to interactions between environmental and genetic lesions during aging. Hence, we speculated 11 that the ADAMTSL3-SH3GL3 frequency in human populations was higher than 1.5%. Most 12 ADAMTSL3-SH3GL3 was dormant or differentially expressed at younger ages and activated by 13 interactions between environmental and genetic lesions during aging. We named this dormant or 14 differentially expressed fusion gene inherited from their parents the dormant or differentially-expressed 15 HFG (dHFG). Hence, ADAMTSL3-SH3GL3 was the first potential dHFG. Table 3 showed that 16 SH3GL3-ADAMTSL3 and ADAMTSL3-SH3GL3 were early-stage aging and neurological disease 17 biomarkers.

18

19 Discussion

We analyzed the RNA-Seq data of the NYGC ALS Consortium and identified fusion transcripts from
ASL, OND, and NNC. Many NNC fusion transcripts were highly recurrent. For example, *ADAMTSL3- SH3GL3* was detected in 100% of 12 NNC samples and is consistent with our previous finding that *ADAMTSL3-SH3GL3* was detected in 87.5% of eight AD-healthy controls³⁶. If structural variants
generating a fusion gene per individual had a rate of 3.6x10⁻² ^{29, 30}, generating seven and twelve
The First Insight into the Hereditary Fusion Gene Landscape of ASL

Yang

ADAMTSL3-SH3GL3 simultaneously in a dataset was 7.8%10⁻¹¹ and 4.7%10⁻¹⁸. Such low chances 1 from two different sources^{18, 36} made it mathematically impossible for ADAMTSL3-SH3GL3 to be 2 3 generated via random somatic genomic abnormalities. These observations supported that fusion 4 transcripts generated via genomic alterations in healthy controls were potential HFGs. Hence, we 5 developed a novel approach using fusion transcripts of NNC to discover HFGs. We used a 6 mathematical model and blast against AceView and NCBI and identified 204 HFGs encoding 233 HFG 7 transcripts. Bioinformatic analysis showed that 33 (16.2%) HFGs were from tandem gene duplications. 8 As we described previously, SCIF was not intended to discover fusion transcripts generated via tandem 9 duplications, and their discovery was due to gene duplications and pseudogenes²⁴. Hence, HFGs 10 produced via genomic tandem duplications were essential biomarkers for diseases and complex traits 11 and might be significantly underestimated.

12

13 We combined 204 HFGs discovered from NNC and the previously-curated 1180 MZ HFGs into the 14 HFG dataset to analyze the fusion transcripts of 154 RNA-Seq data from 77 ASL patients. We 15 discovered 346 HFGs encoding 819 HFG transcripts from ASL patients, whose recurrent frequencies 16 ranged from 1 (1.3%) to 76 (98.7) of 77 ASL patients. Out of 819 HFG transcripts, 345 (42.1%) HFG 17 transcripts were detected in only one of 77 ASL patients and were shown to be causal HFGs and lowly-18 expressed HFG transcripts. When a cutoff of recurrent frequency was set at 10%, we identified 147 19 HFGs coding for 188 HFG transcripts ranging from 10.4% to 98.7%. As described above, HFGs 20 discovered from 12 NNC samples were extremely recurrent, some were detected in all 12 NNC 21 samples, and the NNC genotypes were distorted. So, we have yet to discover any reasons which can 22 explain these HFG genotype distortions. Hence, we selected 133 GTEx brain cortexes as healthy 23 controls. Table 1 showed that 139 HFGs were 1.2-121 folds higher than their GTEx brain cortex 24 counterparts and were shown by statistical analysis to be associated with ASL. Out of 139 HFGs The First Insight into the Hereditary Fusion Gene Landscape of ASL

Yang

1 associated with ASL, Table 2 showed sixteen HFGs with recurrent frequencies of ≥50%, some of which 2 were also highly recurrent in OND, AD, and MTLE. 139 HFGs associated with ASL were four folds of 3 more than 30 mutated genes associated with ASL. The HFG numbers and their recurrent frequencies 4 suggested that HFGs were much more critical "inherited" genetic factors than the mutated genes⁶⁸. 5 Hence, we can conclude that highly recurrent HFGs are the missing ASL heritability. More importantly, 6 many neurological diseases such as ASL, MTLE, and AD shared highly recurrent HFGs and supported 7 that these neurological diseases had common pathophysiological mechanisms²⁸. They potentially 8 allowed us to develop more effective novel therapeutic drugs and methods to treat and cure 9 neurological diseases.

10

11 One of the most highly-recurrent HFGs was ADAMTSL3-SH3GL3, an inversion of SH3GL3-ADAMTSL3 12 EFG (Fig.3). ADAMTSL3-SH3GL3 HFG was detected in at least 82.4% of ASL, OND, AD, and MTLE 13 samples. More surprisingly, it was detected in 100% and 87.5% of 12 NNC samples and nine AD 14 controls. Even though OND, AD, and TMLE data sizes are relatively small, the divergent sources of 15 these data compensated for shortcomings. These data suggested that ADAMTSL3-SH3GL3 would be 16 more recurrent among general populations than 1.5% of GTEx brain cortexes. To address this 17 apparent disparity, we could take a lesson from SH3GL3-ADAMTSL3 EFG, the ancestors of 18 ADAMTSL3-SH3GL3. Table 3 showed that SH3GL3-ADAMTSL3 was almost ubiquitously expressed in 19 ASL, OND, AD, MTLE, and two controls. In comparison, it was detected in 7.5% of 133 GTEx brain cortexes and suggested that SH3GL3-ADAMTSL3³⁸ and ADAMTSL3-SH3GL3^{20, 37} behaved similarly. 20 21 Since SH3GL3-ADAMTSL3 EFG can be treated as a permanent HFG with a recurrent frequency of 22 100%, we speculated that ADAMTSL3-SH3GL3 had a much higher recurrent frequency than 1.5% of 23 GTEx brain cortexes and was activated to be expressed by interactions between genetic and 24 environmental lesions during aging. We named this type of HFG the dormant or differentially-The First Insight into the Hereditary Fusion Gene Landscape of ASL

Yang

expressed HFGs. We needed genotyping general populations to validate if *ADAMTSL3-SH3GL3* was
 a dHFG or if other factors caused the disparity between neurological disease-related data and GTEx
 brain cortexes.

- 4
- 5

6 To study whether hereditary fusion genes were associated with ASL, AD, MTLE, and other neurological 7 diseases, one of the most critical issues was the accuracy and reproducibility of fusion transcripts 8 discovered from RNA-Seq data. Alternatively, the software systems to discover fusion transcripts from 9 RNA-Seg data were essential to generate accurate and reproducible fusion transcript data. Since more 10 than 20 software systems were available, scientific communities needed more standards to evaluate the qualities of these systems ³⁹. In this study, we showed 22 ASL patients had frontal cortex, medial 11 12 motor cortex, and lateral cortex and were more like three data duplications. It is important to note that 13 we should avoid such a strategy to study epigenetic fusion genes. As shown in STable 2, we identified 14 29 HFGs encoding 38 HFG transcripts expressed in all three brain tissues. For example, ZNF528-15 ZNF880 and SNORD114 -MEG8 were observed in the frontal cortex, medial motor cortex, and lateral 16 cortex of 21 of 22 ASL patients and showed 100% reproducibility of fusion transcripts generated by 17 SCIF. Hence, we recommended that scientists and bioinformaticians use these data as reference 18 standards to select a suitable software system for one's research projects. Since our fusion transcripts 19 could be traced to each RNA-Seg read, one could use fusion junction sequences provided in this study 20 to search the original datasets to validate HFG fusion transcripts, most of which were reproducible 21 except for fusion transcripts generated by DNA duplications.

- 22
- 23
- 24

Yang

1	
2	
3	
4	
5	
6	
7	
8	
9	Acknowledges
10	We appreciate the support from The Target ALS Human Postmortem Tissue Core, the New York
11	Genome Center for Genomics of Neurodegenerative Disease, the Amyotrophic Lateral Sclerosis
12	Association, and the Tow Foundation. We thank the support from the science and technology
13	innovation Program of Hunan Province (Program #: 2021SK4014).
14	
15	
16	
17	
18	
19	
20	References
21	1. Siddique N, Siddique T. Amyotrophic Lateral Sclerosis Overview. In: Adam MP, Everman DB,
22	Mirzaa GM, et al., eds. GeneReviews((R)). Seattle (WA)1993.
23	2. Chio A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: A critical review.
24	Amyotroph Lateral Scler 2009;10:310-323.
	The First Insight into the Hereditary Fusion Gene Landscape of ASL

Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol
 2020;27:1918-1929.

3 4. Nguyen HP, Van Broeckhoven C, van der Zee J. ALS Genes in the Genomic Era and their
4 Implications for FTD. Trends Genet 2018;34:404-423.

5 5. Parobkova E, Matej R. Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degenerations:

6 Similarities in Genetic Background. Diagnostics 2021;11.

7 6. Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nature

8 neuroscience 2014;17:17-23.

9 7. Alsultan AA, Waller R, Heath PR, Kirby J. The genetics of amyotrophic lateral sclerosis:

10 current insights. Degenerative neurological and neuromuscular disease 2016;6:49-64.

11 8. Suzuki N, Nishiyama A, Warita H, Aoki M. Genetics of amyotrophic lateral sclerosis: seeking

12 therapeutic targets in the era of gene therapy. J Hum Genet 2023;68:131-152.

13 9. Chia R, Chio A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis:

14 diagnostic and clinical implications. The Lancet Neurology 2018;17:94-102.

15 10. Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS Genetics, Mechanisms,

16 and Therapeutics: Where Are We Now? Front Neurosci 2019;13:1310.

17 11. International HapMap C, Frazer KA, Ballinger DG, et al. A second generation human haplotype

- 18 map of over 3.1 million SNPs. Nature 2007;449:851-861.
- 19 12. Benyamin B, He J, Zhao Q, et al. Cross-ethnic meta-analysis identifies association of the GPX3-
- 20 TNIP1 locus with amyotrophic lateral sclerosis. Nature communications 2017;8:611.

Yang

1	13.	van Es MA, Veldink JH, Saris CG, et al. Genome-wide association study identifies 19p13.3
2	(UNC	13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet
3	2009;4	41:1083-1087.
4	14.	Laaksovirta H, Peuralinna T, Schymick JC, et al. Chromosome 9p21 in amyotrophic lateral
5	scleros	sis in Finland: a genome-wide association study. The Lancet Neurology 2010;9:978-985.
6	15.	Udine E, Jain A, van Blitterswijk M. Advances in sequencing technologies for amyotrophic
7	lateral	sclerosis research. Molecular neurodegeneration 2023;18:4.
8	16.	van Rheenen W, van der Spek RAA, Bakker MK, et al. Common and rare variant association
9	analys	es in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and
10	neuroi	n-specific biology. Nat Genet 2021;53:1636-1648.
11	17.	Tam OH, Rozhkov NV, Shaw R, et al. Postmortem Cortex Samples Identify Distinct Molecular
12	Subty	pes of ALS: Retrotransposon Activation, Oxidative Stress, and Activated Glia. Cell reports
13	2019;2	29:1164-1177 e1165.
14	18.	Brown AL, Wilkins OG, Keuss MJ, et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing
15	and de	epletion of UNC13A. Nature 2022;603:131-137.
16	19.	Theunissen F, Flynn LL, Anderton RS, et al. Structural Variants May Be a Source of Missing
17	Herita	bility in sALS. Front Neurosci 2020;14:47.
18	20.	Raghav Y, Dilliot AA, Petrozziello T, et al. Identification of gene fusions associated with
19	amyot	rophic lateral sclerosis. medRxiv 2022:2022.2006.2004.22275962.
20	21.	Conesa A, Madrigal P, Tarazona S, et al. A survey of best practices for RNA-seq data analysis.
21	Genor	ne Biol 2016;17:13.

Yang

1	22.	Zhou JX, Yang X, Ning S, et al. Identification of KANSARL as the first cancer predisposition
2	fusio	n gene specific to the population of European ancestry origin. Oncotarget 2017;8:50594-50607.
3	23.	Fei L, Zhuo N, Zhuo D. The Hereditary and Epigenetic Fusion Gene Signatures of Multiple
4	Myel	oma. bioRxiv 2022:2022.2012.2005.519213.
5	24.	Zhuo D. The First Glimpse of Homo sapiens Hereditary Fusion Genes. Journal of
6	Pharm	nacogenomics & Pharmacoproteomics 2022;13:1-7.
7	25.	Thierry-Mieg D, Thierry-Mieg J. AceView: a comprehensive cDNA-supported gene and
8	transc	cripts annotation. Genome Biol 2006;7 Suppl 1:S12 11-14.
9	26.	Ling F, Zhuo D. Hereditary Fusion Genes Are Associated with the Inheritance of Acute Myeloid
10	Leuke	emia. bioRxiv 2022:2022.2010.2031.514615.
11	27.	Ling F, Zhuo N, Zhuo D. The First Insight into the Epigenetic Fusion Gene Landscape of Acute
12	Myel	oid Leukemia. bioRxiv 2022:2022.2012.2006.519396.
13	28.	Boison D, Aronica E. Comorbidities in Neurology: Is adenosine the common link?
14	Neuro	opharmacology 2015;97:18-34.
15	29.	Conrad DF, Pinto D, Redon R, et al. Origins and functional impact of copy number variation in
16	the hu	uman genome. Nature 2010;464:704-712.
17	30.	Campbell CD, Eichler EE. Properties and rates of germline mutations in humans. Trends Genet
18	2013;	29:575-584.
19	31.	Group PTC, Calabrese C, Davidson NR, et al. Genomic basis for RNA alterations in cancer.
20	Natur	re 2020;578:129-136.
21	32.	Iafrate AJ, Feuk L, Rivera MN, et al. Detection of large-scale variation in the human genome.
22	Nat C	Genet 2004;36:949-951.

Yang

1	33.	Lee AJ, Raghavan NS, Bhattarai P, et al. FMNL2 regulates gliovascular interactions and is
2	associ	iated with vascular risk factors and cerebrovascular pathology in Alzheimer's disease. Acta
3	Neuro	opathol 2022;144:59-79.
4	34.	Raggio V, Dell'Oca N, Simoes C, et al. Whole genome sequencing reveals a frameshift mutation
5	and a	large deletion in YY1AP1 in a girl with a panvascular artery disease. Hum Genomics 2021;15:28.
6	35.	Wild KT, Gordon T, Bhoj EJ, et al. Congenital diaphragmatic hernia as a prominent feature of a
7	SPEC	C1L-related syndrome. Am J Med Genet A 2020;182:2919-2925.
8	36.	Scheckel C, Drapeau E, Frias MA, et al. Regulatory consequences of neuronal ELAV-like
9	protei	n binding to coding and non-coding RNAs in human brain. Elife 2016;5.
10	37.	Azatyan A, Zaphiropoulos PG. Circular and Fusion RNAs in Medulloblastoma Development.
11	Cance	ers 2022;14.
12	38.	Singh S, Qin F, Kumar S, et al. The landscape of chimeric RNAs in non-diseased tissues and
13	cells.	Nucleic Acids Res 2020;48:1764-1778.
14	39.	Simoneau J, Dumontier S, Gosselin R, Scott MS. Current RNA-seq methodology reporting limits
15	reproc	ducibility. Briefings in bioinformatics 2021;22:140-145.
16		
17		

Yang

1 Tables

3 Table 1 Comparisons of the top sixteen HFGs between ASL and GTEx

HFGs	5' Junction Sequence	3' Junction Sequence	ASL (77)		GTEx (133) # %		Folds	р
ZNF528-ZNF880	CATCAAAGGTGTGAACACAG	GGACACTTGGCATTCAGGGA	# 76	% 98.7	# 6	% 4.5	20.9	***
SNORD114MEG8_ a	GAGCCTGGACACTAATAGAA	GATAAGTCTACTTTTCTTCC	70	90.9	1	4.5 0.8	119.9	* * *
TRNAN35-FAM91A3P	TGAGGACTGCCTGTTTGCAG	GCTCTGATTGTACTTTCTCC	69	89.6	42	0.8 31.6	1.8	* * *
ADAMTSL3-SH3GL3 a	CTTATCGCTATGATGACCAG	GTAGAACAAGTCAGCCAGTT	67	87.0	42 2	1.5	56.9	* * *
SNORD114 -MEG8 b	TGTGTCACAGGAAGACTCTT	GATAAGTCTACTTTTCTTCC	65	84.4	1	0.8	111.3	* * *
SDHAP2-SDHAP2 a	AATATCTGGACTTTGAAATT	TGCACAGCCAGAGAACAACA	60	77.9	1	0.8	102.6	* * *
YY1AP1-YY1AP1 a	TTCACCAAGGCTGAGGACAA	TTCCAAGATGAGATGGGATT	58	75.3	1	0.8	99.2	***
SDHAP2-SDHAP2 b	TAGACTGGATGCAGAGCATG	TGCACAGCCAGAGAACAACA	57	74.0	1	0.8	97.5	***
ERMP1-KIAA2026	GTTACGTGGATGTTTGTAAC	TGAGCTTTCTCTTAAGTGTG	57	74.0	1	0.8	97.5	***
TRNAN35-SRGAP2P2	TGAGGACTGCCTGTTTGCAG	GCAAGTGAACCGGAGCAAAC	56	74.0	6	4.5	15.1	***
ADAMTSL3-SH3GL3 b	TGCACTCTCCCCTCCCGCAG	GTAGAACAAGTCAGCCAGTT	54	70.1	1	4.5 0.8	92.3	***
FMNL2-FMNL2	GGAAGACATTCTGCACTGCG	GAACGATTCCAGGTGAAGAA	53	68.8	2	1.5	44.8	* * *
SMOX-RAD54L2	CCAAAGTGCTGGAATTACAG	CACCCCTGCAGTGGACCATG	50	64.9	4	3.0	20.6	***
PTPRS-PHACTR3	CCGAGTGGCTGGGACTACAG	ATGAGATGGACCAAACGCCC	47	61.0	4 16	3.0 12.0	4.1	* * *
FAM168B-NUCB2	CAGGTCGCCGCCGCGCGCGCG	TAGAGACGAGGTTTCACCGT	47	55.8	24	12.0	2.1	* * *
TMEFF1-RWDD2B	AAGAGGACCATGCTACTCTG	GCTGGAGTGCAGTGGCGCGA	42	54.5	3	2.3	23.2	***
TRNAN35-SEC22B	TGAGGACTGCCTGTTTGCAG	CTACATTATTGAGCAGGGGG	41	53.2	1	0.8	69.8	***
SNORD114 -MEG8 c	GAGCCTGGACACTAATAGAA	AATGGAGGCTCCAGAGTGAA	41	53.2	9	6.8	6.9	***
YY1AP1-YY1AP1 b	GGCTCCCATTCTGGTTAAAG	CGAATGAATTTCCCTGTTTG	39	50.6	1	0.8	66.4	* * *
PITPNM3-KIAA0753	GAAACTGGACGAGCATCAAG	TGTTTCTGCCACCCACTTAG	39	50.6	1	0.8	66.4	***
SPECC1L-SPECC1L	CAAATCCAAGATTAGCACAG	ATTTGCTTGTAAATGCATCA	39	50.6	1	0.8	66.4	* * *
SFECCIL-SFECCIL	CAAATCCAAGATTAGCACAG	ATTIGETIGIAATGEATCA	39	50.0	Т	0.8	00.4	

Yang

Table 2 Distributions of the top sixteen HFGs among OND, MTLE, and AD

HFGs	ASL (77)		ON	OND (7)		.E (17)	AD (9)		
HFGS	#	%	#	%	#	%	#	%	
ZNF528-ZNF880	76	98.7	6	85.7	16	94.1	8	88.9	
SNORD114MEG8_ a	70	90.9	5	71.4	14	82.4	5	55.6	
TRNAN35-FAM91A3P	69	89.6	5	71.4	4	23.5	4	44.4	
ADAMTSL3-SH3GL3 a	67	87.0	7	100.0	14	82.4	9	100.0	
SNORD114MEG8_ b	65	84.4	7	100.0	13	76.5	5	55.6	
SDHAP2-SDHAP2 a	60	77.9	4	57.1	14	82.4	6	66.7	
YY1AP1-YY1AP1 a	58	75.3	6	85.7	12	70.6	0	0.0	
SDHAP2-SDHAP2 b	57	74.0	4	57.1	9	52.9	3	33.3	
ERMP1-KIAA2026	57	74.0	5	71.4	4	23.5	4	44.4	
TRNAN35-SRGAP2P2	56	72.7	4	57.1	5	29.4	4	44.4	
ADAMTSL3-SH3GL3 b	54	70.1	6	85.7	9	52.9	4	44.4	
FMNL2-FMNL2	53	68.8	7	100.0	9	52.9	0	0.0	
SMOX-RAD54L2	50	64.9	3	42.9	7	41.2	0	0.0	
PTPRS-PHACTR3	47	61.0	5	71.4	1	5.9	0	0.0	
FAM168B-NUCB2	43	55.8	3	42.9	4	23.5	0	0.0	
TMEFF1-RWDD2B	42	54.5	6	85.7	5	29.4	0	0.0	
TRNAN35-SEC22B	41	53.2	5	71.4	4	23.5	0	0.0	
SNORD114MEG8_ c	41	53.2	5	71.4	5	29.4	0	0.0	
YY1AP1-YY1AP1 b	39	50.6	4	57.1	4	23.5	0	0.0	
PITPNM3-KIAA0753	39	50.6	3	42.9	4	23.5	2	22.2	
SPECC1L-SPECC1L	39	50.6	6	85.7	8	47.1	0	0.0	

Yang

1				
2				
3				
4				
5				
6				

7

Table 3 ADAMTSL3-SH3GL3 behaved like SH3	<i>GL3-ADAMTSL3</i> and was a pot	ential dormant HFG.
Data	SH3GL3-ADAMTSL3 (%)	ADAMTSL3-SH3GL3 (%)
Amyotrophic lateral sclerosis (77)	98.7	87.0
Non-neurological controls (12)	100	100
Other neurological disorders (7)	100	100
mesial temporal lobe epilepsy (17)	94.1	82.4
Alzheimer's disease (9)	100	100
Alzheimer's disease control (8)	100	87.5
GTEx brain cortex (133)	7.5	1.5

9

8

[First Authors Last Name] Page 26

1 Figure Legends

2

3 Fig. 1 Identification and characterization of hereditary fusion genes (HFGs) from RNA-4 Seq data of the non-neurological controls (NCC) and amyotrophic lateral sclerosis (ASL). 5 a). characteristics of the amyotrophic lateral sclerosis RNA-Seg dataset (GEO: GSE124439), 6 including 77 amyotrophic lateral sclerosis (ASL) patients, seven patients with other neurological 7 disorders (OND), and 12 non-neurological controls (NNC); b). The procedure of identifying 8 HFGs from 12 NCC individuals; c). The total HFGs used to analyze HFG transcripts of 9 amyotrophic lateral sclerosis, including previously-curated 1180 MZ HFGs and 204 Ctr HFGs; d). The components of HFGs to identify ASL HFGs. 10 11 12 Fig. 2 Potential genomic mechanisms to generate ZNF528-ZNF880, TRNAN35-FAM91A3P, 13 and SNORD114 -MEG8 . a). A potential local inversion to form ZNF528-ZNF880; b) A 14 putative local translocation to produce TRNAN35-FAM91A3P; and c). A potential local 15 inversion to generate SNORD114 -MEG8, Black and red horizontal arrows indicated 5' and 3' 16 genes of HFGs. Gray horizontal arrows were genes surrounding 5' and 3' genes. The vertical 17 arrows showed potential genomic rearrangements. 18 19 Fig. 3 A potential local inversion of SH3GL3-ADAMTSL3 to produce ADAMTSL3-SH3GL3. 20 Two identical-stand neighboring SH3GL3 and ADAMTSL3 genes (a) produced an SH3GL3-21 ADAMTSL3 readthrough pre-mRNA (b), which was spliced to form three of thirteen SH3GL3-22 ADAMTSL3 EFG transcripts(c). SH3GL3-ADAMTSL3 was locally inverted or locally amplified to 23 ADAMTSL3-SH3GL3 hereditary fusion gene (HFG) (d), transcribed into ADAMTSL3-SH3GL3 24 pre-mRNAs €, which was spliced into three examples of 42 ADAMTSL3-SH3GL3 HFG

[First Authors Last Name] Page 27

- 1 transcripts. Black and red horizontal solid arrows showed 5' and 3' genes of HFGs. Black and
- 2 red rectangles were exons. Black triangles were introns. The double dashed lines were
- 3 putative breakpoints. Horizontal dashed lines indicated omitted exons and introns. An open
- 4 arch arrow indicated a local translocation or genomic amplification.

5

[First Authors Last Name] Page 28

1 Supplemental Materials

2 NYGC ALS Consortium

Hemali Phatnani⁵, Justin Kwan⁶, Dhruv Sareen^{7,8}, James R. Broach9, Zachary Simmons¹⁰, 3 Ximena Arcila-Londono¹¹, Edward B. Lee¹², Vivianna M. Van Deerlin¹², Neil A. Shneider¹³, 4 Ernest Fraenkel¹, Lyle W. Ostrow¹⁴, Frank Baas^{15,16}, Noah Zaitlen¹⁷, James D. Berry^{18,19}, Andrea 5 Malaspina^{19,20,21}, Pietro Fratta²², Gregory A. Cox²³, Leslie M. Thompson^{24,25}, Steve Finkbeiner²⁶, 6 Efthimios Dardiotis²⁷, Timothy M. Miller²⁸, Siddharthan Chandran²⁹, Suvankar Pal²⁹, Eran 7 Hornstein³⁰, Daniel J. MacGowan³¹, Terry Heiman-Patterson³², Molly G. Hammell³³, Nikolaos, A. 8 Patsopoulos^{34,35}, Oleg Butovsky³⁶, Joshua Dubnau³⁷, Avindra Nath³⁸, Robert Bowser^{39,40}, 9 Matthew Harms⁴¹, Eleonora Aronica⁴², Mary Poss⁴³, Jennifer Phillips-Cremins⁴⁴, John Crary⁴⁵, 10 Nazem Atassi⁴⁶, Dale J. Lange^{47,48}, Darius J. Adams^{49,50}, Leonidas Stefanis^{51,52}, Marc Gotkine⁵³, 11 Robert H. Baloh^{54,55}, Suma Babu¹⁹, Towfique Raj⁵⁶, Sabrina Paganoni⁵⁷, Ophir Shalem^{58,59}, 12 Colin Smith^{60,61}, Bin Zhang⁶², Brent Harris⁶³, Iris Broce⁶⁴, Vivian Drory⁶⁵, John Ravits⁶⁶, Corev 13 McMillan⁶⁷, Vilas Menon⁶⁸, Lani Wu⁶⁹, Steven Altschuler⁶⁹, Yossef Lerner⁷⁰, Rita Sattler⁷¹, 14 Kendall Van Keuren-Jensen⁷². Orit Rozenblatt-Rosen⁷³. Kerstin Lindblad-Toh⁷³. Katharine 15 Nicholson⁷⁴, Peter Gregersen⁷⁵, Jeong-Ho Lee⁷⁶, Sulev Kokos⁷⁷, Stephen Mulio⁷⁸, & Bryan J. 16 Traynor⁷⁹. 17

18

⁵Center for Genomics of Neurodegenerative Disease (CGND), New York Genome Center, New York, NY, USA. ⁶Department of Neurology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA. ⁷Cedars-Sinai Department of Biomedical Sciences, Board of Governors Regenerative Medicine Institute and Brain Program, Cedars-Sinai Medical Center, University of California, Los Angeles, CA, USA. ⁸Department of Medicine, University of California, Los Angeles, CA, USA. ⁹Department of Biochemistry and Molecular Biology, Penn State Institute for

[First Authors Last Name] Page 29

1 Personalized Medicine, The Pennsylvania State University, Hershey, PA, USA. ¹⁰Department of Neurology, The Pennsylvania State University, Hershey, PA, USA. ¹¹Department of Neurology, 2 Henry Ford Health System, Detroit, MI, USA. ¹²Department of Pathology and Laboratory 3 4 Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 5 ¹³Department of Neurology, Center for Motor Neuron Biology and Disease, Institute for Genomic 6 Medicine, Columbia University, New York, NY, USA. ¹Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. ¹⁴Department of Neurology, 7 Johns Hopkins School of Medicine, Baltimore, MD, USA. ¹⁵Department of Neurogenetics. 8 Academic Medical Centre, Amsterdam, The Netherlands. ¹⁶Leiden University Medical Center, 9 10 Leiden, The Netherlands. ¹⁷Department of Medicine, Lung Biology Center, University of California, San Francisco, CA, USA. ¹⁸ALS Multidisciplinary Clinic, Neuromuscular Division, 11 12 Department of Neurology, Harvard Medical School, Boston, MA, USA. ¹⁹Neurological Clinical ¹⁹Centre for 13 Research Institute, Massachusetts General Hospital, Boston, MA, USA. 14 Neuroscience and Trauma, Blizard Institute, Barts, Queen Mary University of London, London, 15 UK. 20 The London School of Medicine and Dentistry, Queen Mary University of London, 16 London, UK. ²¹Department of Neurology, Basildon University Hospital, Basildon, UK. 22 Institute of Neurology, National Hospital for Neurology and Neurosurgery, University College 17 18 London, London, UK. 23 The Jackson Laboratory, Bar Harbor, ME, USA. ²⁴Department of 19 Psychiatry and Human Behavior, Department of Biological Chemistry, School of Medicine, 20 University of California, Irvine, CA, USA.²⁵Department of Neurobiology and Behavior, School of 21 Biological Sciences, University of California, Irvine, CA, USA.²⁶Taube/Koret Center for 22 Neurodegenerative Disease Research, Roddenberry Center for Stem Cell Biology and Medicine, Gladstone Institute, San Francisco, CA, USA.²⁷Department of Neurology and 23 ²⁸Department of Neurology, 24 Sensory Organs, University of Thessaly, Thessaly, Greece. The First Insight into the Hereditary Fusion Gene Landscape of ASL

[First Authors Last Name] Page 30

1 Washington University in St Louis, St Louis, MO, USA.²⁹Centre for Clinical Brain Sciences, 2 Anne Rowling Regenerative Neurology Clinic, Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK. ³⁰Department of Molecular 3 4 Genetics, Weizmann Institute of Science, Rehovot, Israel. ³¹Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ³²Center for Neurodegenerative 5 6 Disorders, Department of Neurology, the Lewis Katz School of Medicine, Temple University, 7 Philadelphia, PA, USA. ³³Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA. 34 8 Computer Science and Systems Biology Program, Ann Romney Center for Neurological 9 Diseases, Department of Neurology and Division of Genetics in Department of Medicine, 10 Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. ³⁵Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA. ³⁶Ann Romney Center 11 12 for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 13 USA. 37 Department of Anesthesiology, Stony Brook University, Stony Brook, NY, USA. 14 ³⁸Section of Infections of the Nervous System, National Institute of Neurological Disorders and 15 Stroke, NIH, Bethesda, MD, USA. 39 Department of Neurology, Barrow Neurological Institute, 16 St Joseph's Hospital, Phoenix, AZ, USA. ⁴⁰Medical Center, Department of Neurobiology, Barrow Neurological Institute, St Joseph's Hospital and Medical Center, Phoenix, AZ, USA. 17 18 ⁴¹Department of Neurology, Division of Neuromuscular Medicine, Columbia University, New 19 York, NY, USA. ⁴²Department of Neuropathology, Academic Medical Center, University of 20 Amsterdam, Amsterdam, The Netherlands. ⁴³Department of Biology and Veterinary and 21 Biomedical Sciences, The Pennsylvania State University, University Park, PA, USA. 44 New 22 York Stem Cell Foundation, Department of Bioengineering, School of Engineering and Applied Sciences, University of Pennsylvania, Philadelphia, PA, USA. ⁴⁵Department of Pathology, 23 24 Fishberg Department of Neuroscience, Friedman Brain Institute, Ronald M. Loeb Center for The First Insight into the Hereditary Fusion Gene Landscape of ASL

[First Authors Last Name] Page 31

1 Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 46 2 Department of Neurology, Harvard Medical School, Neurological Clinical Research Institute, 3 Massachusetts General Hospital, Boston, MA, USA. 47 Department of Neurology, Hospital for 4 Special Surgery, New York, NY, USA. ⁴⁸Weill Cornell Medical Center, New York, NY, USA. 49 5 Medical Genetics, Atlantic Health System, Morristown Medical Center, Morristown, NJ, USA. 50 Overlook Medical Center, Summit, NJ, USA. ⁵¹Center of Clinical Research, Experimental 6 7 Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, Greece. ⁵²1st Department of Neurology, Eginition Hospital, Medical 8 School, National and Kapodistrian University of Athens, Athens, Greece. ⁵³Neuromuscular/EMG 9 10 service and ALS/Motor Neuron Disease Clinic, Hebrew University-Hadassah Medical Center, 11 Jerusalem, Israel.⁵⁴ Board of Governors Regenerative Medicine Institute, Los Angeles, CA. 12 USA. ⁵⁵Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 56 13 Departments of Neuroscience, Genetics and Genomic Sciences, Ronald M. Loeb Center for 14 Alzheimer's disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 57 Harvard Medical School, Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation 15 16 Hospital, Boston, MA, USA. 58 Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. ⁵⁹Department of Genetics, Perelman School of 17 18 Medicine, University of Pennsylvania, Philadelphia, PA, USA. ⁶⁰Centre for Clinical Brain 19 Sciences, University of Edinburgh, Edinburgh, UK.⁶¹Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK. ⁶²Department of Genetics 20 21 and Genomic Sciences, Icahn Institute of Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ⁶³Department of Neuropathology, Georgetown 22 23 Brain Bank, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA. ⁶⁴Neuroradiology Section, Department of Radiology 24 The First Insight into the Hereditary Fusion Gene Landscape of ASL

[First Authors Last Name] Page 32

1 and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA. 2 ⁶⁵Neuromuscular Diseases Unit, Department of Neurology, Tel Aviv Sourasky Medical Center, 3 Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. ⁶⁶Department of 4 Neuroscience, University of California San Diego, La Jolla, CA, USA. ⁶⁷Department of 5 Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. 6 ⁶⁸Department of Neurology, Columbia University Medical Center, New York, NY, USA. 7 ⁶⁹Department of Pharmaceutical Chemistry, University of California San Francisco, San 8 Francisco, CA, USA, 70 Hadassah Hebrew University, Jerusalem, Israel, ⁷¹Department of 9 Translational Neuroscience, Barrow Neurological Institute, Phoenix, AZ, USA. 72 The 10 Translational Genomics Research Institute (TGen), Phoenix, AZ, USA. ⁷³Broad Institute, 11 Cambridge, MA, USA. 74 Massachusetts General Hospital, Boston, MA, USA. 75 Institute of 12 Molecular Medicine, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, 13 NY, USA. 76 Korea Advanced Institute of Science and Technology (KAIST), Daejeon, South 14 ⁷⁷Perron Institute for Neurological and Translational Science, Nedlands, Western Korea. Australia. Australia. ⁷⁸Integrative Immunobiology Section, National Institute of Allergy and 15 16 Infectious Disease, NIH, Bethesda, MD, USA. ⁷⁹Neuromuscular Disease Research Section, 17 National Institute of Aging, NIH, Bethesda, MD, USA

18


Supplemental Table 1: Lists of hereditary fusion genes (HFGs) discovered from the non neurological controls (NNC)
 21

Supplemental Table 2: Lists of NNC HFGs formed via tandem gene duplications
 23

[First Authors Last Name] Page 33

1	Supplemental Table 3: Lists of HFGs that were discovered in amyotrophic lateral
2	sclerosis and present in the frontal cortex, medial motor cortex, and lateral motor cortex
3	
4	Supplemental Table 4: Lists and recurrent frequencies of HFGs present in the frontal
5	cortex, medial motor cortex, and lateral motor cortex of 22 ASL patients
6	
7	Supplemental Table 5: Comparative analysis of recurrent frequencies of HFGs between
8	ASL patients and GTEx brain cortexes
9	
10	
11	Supplemental Fig.1 Sequence alignment of conceptual ZNF528-ZNF880 fusion
12	protein and ZNF880 protein. Dashed line indicated the sequence gap.
13	
14	Supplemental Fig.2 Sequence alignment of conceptual FMNL2-FMNL2 fusion
15	protein and formin like 2 protein. Dashed line indicated the sequence gap.
16	
17	Supplemental Fig.3 Sequence alignment of conceptual YY1AP1-YY1AP1 fusion
18	protein and YY1 associated protein 1. Dashed line indicated the sequence gap.

Fig.1 a



b

гıg.∠

